Such findings highlight the potential for exploring ncRNA-based therapeutics for ncRNA that have a direct metabolic effect, such as MNXAS-1, to exploit metabolic vulnerabilities in MYC-driven cancers. The gene discussed is MYC; the disease is cancer.